Why the study?
To develop a new technique for quicker determination of CYP4F2 rs3093135 and CYP2C19 rs4244285 variants directly from blood and attempt clinical application.
Do CYP2C19 and CYP4F2 variants predict bleeding events in STEMI patients treated with ticagrelor?
Do CYP2C19 and CYP4F2 variants predict bleeding events in STEMI patients treated with ticagrelor?
Direct blood PCR for CYP2C19 and CYP4F2 variants may help predict bleeding risk in STEMI patients treated with ticagrelor.
Answers are grounded in this paper and cite their sources.
New direct-blood PCR enables rapid CYP genotyping in STEMI; leaves open clinical utility for bleeding risk stratification.
Aims: The goals of this study were to develop a new technique that could pave the way for a quicker determination of CYP4F2 rs3093135 and CYP2C19 rs4244285 variants directly from a patient’s blood and to attempt to apply this technique in clinical practice. Patients & methods: The study included 144 consecutive patients admitted with ST elevation myocardial infarction. A blood-direct PCR and real-time PCR were used to detect variants of interest. Results & conclusion: Patients with bleeding events had the CYP2C19 GG (*1*1) variant more frequently than patients without bleeding events. The CYP4F2 TT variant was more frequently detected in patients with bleeding events 3 months after hospitalization.
No takes yet. Share an insight, caveat, or question.
Tatarūnas et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: